Innate Pharma is a Marseille antibody company whose equity now prices a partner-funded survival story rather than a going-concern collapse, because the Sobi license on lacutamab swapped most of the commercial upside in cutaneous T-cell lymphoma for the cash that lets the confirmatory study start, leaving shareholders with a royalty, a late-stage AstraZeneca option in lung cancer, and an early nectin conjugate that still has to prove it is more than a scientific footnote.
The Sobi Lacutamab License, announced in August and described as effective after antitrust waiting periods this week, is the event that changes the balance sheet rather than the science. Sobi pays $75M at close and can add $40M of near-term Sézary development milestones, with a much larger contingent package behind an option on full development rights and later commercial events, plus tiered double-digit royalties. That structure is how a company that finished March with only €25.4 million of cash and a stated runway into the third quarter of this year buys the right to open confirmatory enrollment without drawing the unused at-the-market equity program.
The tension is that the same contract that saves the equity also caps it. Innate runs the confirmatory study and keeps the filing work, but Sobi takes exclusive global commercialization on an accelerated approval and can take the rest of development after a positive readout, so the asset that justified Breakthrough Therapy Designation last year is no longer a wholly owned late-stage story. The market already treated the announcement as a relief rally rather than a re-rating. The ADS jumped from about $1.73 before the announcement toward $2.54 within a few sessions and has since given most of that move back, which is what a thin-trading micro-cap does when investors decide the cash is real and the royalty is still an option.
Two readouts still sit on the calendar before the new cash is a full answer. AstraZeneca's fully enrolled Stage III lung study of monalizumab is scheduled to read out in the second half of this year, and first patients in the lacutamab confirmatory program are described as arriving early next year, with IPH4502 dose-escalation data due around year-end.